These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33565908)

  • 1. Serum neurofilament light in MS: The first true blood-based biomarker?
    Thebault S; Bose G; Booth R; Freedman MS
    Mult Scler; 2022 Sep; 28(10):1491-1497. PubMed ID: 33565908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of serum neurofilament as biomarker for multiple sclerosis.
    Bittner S; Oh J; Havrdová EK; Tintoré M; Zipp F
    Brain; 2021 Nov; 144(10):2954-2963. PubMed ID: 34180982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.
    Sen MK; Hossain MJ; Mahns DA; Brew BJ
    J Neurol; 2023 Apr; 270(4):1908-1930. PubMed ID: 36520240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
    Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neurofilament-light concentration and real-world outcome in MS.
    Anderson V; Bentley E; Loveless S; Bianchi L; Harding KE; Wynford-Thomas RA; Joseph F; Giovannoni G; Gnanapavan S; Robertson NP; Marta M; Tallantyre EC
    J Neurol Sci; 2020 Oct; 417():117079. PubMed ID: 32781395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management.
    Freedman MS; Gnanapavan S; Booth RA; Calabresi PA; Khalil M; Kuhle J; Lycke J; Olsson T;
    EBioMedicine; 2024 Mar; 101():104970. PubMed ID: 38354532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives.
    Jakimovski D; Dwyer MG; Bergsland N; Weinstock-Guttman B; Zivadinov R
    Neurodegener Dis Manag; 2021 Aug; 11(4):329-340. PubMed ID: 34196596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years.
    Friedova L; Motyl J; Srpova B; Oechtering J; Barro C; Vodehnalova K; Andelova M; Noskova L; Fialová L; Havrdova EK; Horakova D; Benedict RH; Kuhle J; Uher T
    Mult Scler Relat Disord; 2020 Nov; 46():102534. PubMed ID: 33032055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis.
    Galetta K; Deshpande C; Healy BC; Glanz B; Ziehn M; Saxena S; Paul A; Saleh F; Collins M; Gaitan-Walsh P; Castro-Mendoza P; Weiner HL; Chitnis T
    Ann Clin Transl Neurol; 2021 Mar; 8(3):631-638. PubMed ID: 33492760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.
    Reinert MC; Benkert P; Wuerfel J; Michalak Z; Ruberte E; Barro C; Huppke P; Stark W; Kropshofer H; Tomic D; Leppert D; Kuhle J; Brück W; Gärtner J
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32404429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study.
    Hegen H; Berek K; Bsteh G; Auer M; Altmann P; Di Pauli F; Grams A; Milosavljevic D; Ponleitner M; Poskaite P; Schnabl C; Wurth S; Zinganell A; Berger T; Walde J; Deisenhammer F
    EBioMedicine; 2023 May; 91():104573. PubMed ID: 37086651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
    Seiberl M; Feige J; Hilpold P; Hitzl W; Machegger L; Buchmann A; Khalil M; Trinka E; Harrer A; Wipfler P; Moser T
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
    Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
    J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of serum neurofilament light chains levels for diagnosis, treatment monitoring and prognosis in multiple sclerosis].
    Alifirova VM; Kamenskikh EM; Koroleva ES
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):7-13. PubMed ID: 31934983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Huppke B; Reinert MC; Hummel-Abmeier H; Stark W; Gärtner J; Huppke P
    Neurology; 2023 Nov; 101(19):e1873-e1883. PubMed ID: 37748882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.